Literature DB >> 29925281

Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker.

Daniel Heinrich1, Øyvind Bruland2, Theresa A Guise3, Hiroyoshi Suzuki4, Oliver Sartor5.   

Abstract

Since most patients with metastatic castration-resistant prostate cancer (mCRPC) have bone metastases, it is important to understand the potential impact of therapies on prognostic biomarkers, such as ALP. Clinical studies involving mCRPC life-prolonging agents (i.e., sipuleucel-T, abiraterone, enzalutamide, docetaxel, cabazitaxel, and radium-223) have shown that baseline ALP level is prognostic for overall survival, and may be a better prognostic marker for overall survival than prostate-specific antigen in patients with bone-dominant mCRPC. Mechanism of action differences between therapies may partly explain ALP dynamics during treatment. ALP changes can be interpreted within the context of other parameters while monitoring disease activity to better understand the underlying pathology. This review evaluates the current role of ALP in mCRPC.

Entities:  

Keywords:  alkaline phosphatase; biomarker; bone metastases; castration-resistant prostate cancer; mechanism of action; prognostic marker; survival

Mesh：

Substances：

Year:  2018        PMID： 29925281     DOI： 10.2217/fon-2018-0087

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  15 in total

Review 1.  Targeting CD39 in cancer.

Authors:  Achim K Moesta; Xian-Yang Li; Mark J Smyth
Journal:  Nat Rev Immunol       Date:  2020-07-29       Impact factor: 53.106

2.  Enzyme Responsive Rigid-Rod Aromatics Target "Undruggable" Phosphatases to Kill Cancer Cells in a Mimetic Bone Microenvironment.

Authors:  Meihui Yi; Fengbin Wang; Weiyi Tan; Jer-Tsong Hsieh; Edward H Egelman; Bing Xu
Journal:  J Am Chem Soc       Date:  2022-07-18       Impact factor: 16.383

3.  Serum alkaline phosphatase is a prognostic marker in bone metastatic disease of the extremity.

Authors:  Quirina C B S Thio; Aditya V Karhade; Emily Notman; Kevin A Raskin; Santiago A Lozano-Calderón; Marco L Ferrone; Jos A M Bramer; Joseph H Schwab
Journal:  J Orthop       Date:  2020-08-17

4.  Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients.

Authors:  Florian Rosar; Kalle Ribbat; Martin Ries; Johannes Linxweiler; Mark Bartholomä; Stephan Maus; Mathias Schreckenberger; Samer Ezziddin; Fadi Khreish
Journal:  EJNMMI Res       Date:  2020-05-24       Impact factor: 3.138

5.  Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel.

Authors:  Ingeborg E de Kruijff; Anieta M Sieuwerts; Wendy Onstenk; Jaco Kraan; Marcel Smid; Mai N Van; Michelle van der Vlugt-Daane; Esther Oomen-de Hoop; Ron H J Mathijssen; Martijn P Lolkema; Ronald de Wit; Paul Hamberg; Hielke J Meulenbeld; Aart Beeker; Geert-Jan Creemers; John W M Martens; Stefan Sleijfer
Journal:  Cancers (Basel)       Date:  2019-08-20       Impact factor: 6.639

6.  Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment.

Authors:  Viviana Frantellizzi; Arianna Pani; Maria Dea Ippoliti; Alessio Farcomeni; Irvin Aloise; Mirco Colosi; Claudia Polito; Roberto Pani; Giuseppe De Vincentis
Journal:  Radiol Oncol       Date:  2019-12-19       Impact factor: 2.991

7.  Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE.

Authors:  Daniele Santini; Saverio Cinieri; Donatello Gasparro; Roberto Bordonaro; Pamela Francesca Guglielmini; Vincenzo Emanuele Chiuri; Rolando M D'Angelillo; Giovanni Luca Ceresoli; Daniele Fagnani; Mirko Acquati; Manlio Mencoboni; Gaetano Lanzetta; Donata Sartori; Paolo Carlini; Fabiana Panebianco; Patrizia Beccaglia; Giuseppe Procopio
Journal:  J Bone Oncol       Date:  2020-12-02       Impact factor: 4.072

8.  Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.

Authors:  Weelic Chong; Zhenchao Zhang; Rui Luo; Jian Gu; Jianqing Lin; Qiang Wei; Bingshan Li; Ronald Myers; Grace Lu-Yao; William Kevin Kelly; Chun Wang; Hushan Yang
Journal:  BMC Cancer       Date:  2021-06-02       Impact factor: 4.638

9.  A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.

Authors:  Lawrence Fong; Michael J Morris; Andrew J Armstrong; Daniel P Petrylak; Oliver Sartor; Celestia S Higano; Lance Pagliaro; Ajjai Alva; Leonard J Appleman; Winston Tan; Ulka Vaishampayan; Raphaelle Porcu; Darren Tayama; Edward E Kadel; Kobe C Yuen; Asim Datye
Journal:  Clin Cancer Res       Date:  2021-06-09       Impact factor: 13.801

Review 10.  NBD-based synthetic probes for sensing small molecules and proteins: design, sensing mechanisms and biological applications.

Authors:  Chenyang Jiang; Haojie Huang; Xueying Kang; Liu Yang; Zhen Xi; Hongyan Sun; Michael D Pluth; Long Yi
Journal:  Chem Soc Rev       Date:  2021-07-05       Impact factor: 60.615
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.